These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3931664)

  • 21. Effects of the gonadotropin-releasing hormone agonist [D-leu6, desgly-NH2(10), proethylamide9]-GnRH (leuprolide) on R3327-G rat prostatic tumor growth.
    Pollack A; Block NL; Stover BJ; Fuentes MP; Irvin GL
    J Urol; 1984 Feb; 131(2):399-403. PubMed ID: 6422059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of leuprolide on growth of rat prostatic tumor (R 3327) and weight of male accessory sex organs.
    Ichikawa T; Akimoto S; Shimazaki J
    Endocrinol Jpn; 1988 Feb; 35(1):181-7. PubMed ID: 3135178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monthly dosage form of leuprolide approved by FDA.
    Oncology (Williston Park); 1989 Apr; 3(4):139. PubMed ID: 2518158
    [No Abstract]   [Full Text] [Related]  

  • 24. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmaceutical aspects. Nasal and depot formulations of leuprolide.
    Shimamoto T
    J Androl; 1987; 8(1):S14-6. PubMed ID: 3104262
    [No Abstract]   [Full Text] [Related]  

  • 26. Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
    Spitz IM; Chertin B; Fridmans A; Farkas A; Belanger A; Hartman H; Labrie F
    Prostate Cancer Prostatic Dis; 2009; 12(1):100-3. PubMed ID: 18574491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
    Daskivich TJ; Oh WK
    Urology; 2006 May; 67(5):1084.e15-7. PubMed ID: 16698377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical progress with LHRH analogues in prostatic cancer. Proceedings of an international symposium. Monte Carlo, 20 January 1990.
    J Int Med Res; 1990; 18 Suppl 1():1-125. PubMed ID: 2108881
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy over time of LHRH analogs in the treatment of PCa--a prospective analysis using serum testosterone to determine dosing intervals.
    Greil S; Robinson EA; Singal B; Kleer E
    Urology; 2009 Mar; 73(3):631-4. PubMed ID: 19110301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
    Curry EA; Sweeney CJ
    J Urol; 2002 Jul; 168(1):193. PubMed ID: 12050525
    [No Abstract]   [Full Text] [Related]  

  • 31. DES lead-in to use of luteinizing hormone releasing hormone analogs in treatment of metastatic carcinoma of prostate.
    Stein BS; Smith JA
    Urology; 1985 Apr; 25(4):350-3. PubMed ID: 3920802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Testicular histology after prolonged treatment with a gonadotropin-releasing hormone analogue.
    Smith JA; Urry RL
    J Urol; 1985 Apr; 133(4):612-4. PubMed ID: 3920405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Re: A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy.
    Pickles T
    J Urol; 2005 Dec; 174(6):2423-4; author reply 2424. PubMed ID: 16280866
    [No Abstract]   [Full Text] [Related]  

  • 34. Gonadotropin releasing hormone analogue antiandrogen failure secondary to a pituitary adenoma.
    Ogan K; Berger M; Ball R
    J Urol; 1998 Aug; 160(2):497-8. PubMed ID: 9679910
    [No Abstract]   [Full Text] [Related]  

  • 35. Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
    Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
    Int J Urol; 2006 Mar; 13(3):303-4. PubMed ID: 16643633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment with D-Trp-6-LHRH. Plasma levels and gonadotropic response].
    Lahlou N; Duchier J; Feinstein MC; Mauvernay RY; Roger M; Schally AV
    Pathol Biol (Paris); 1984 Oct; 32(8):906-8. PubMed ID: 6209605
    [No Abstract]   [Full Text] [Related]  

  • 37. Regression of rat mammary tumors by a potent luteinizing hormone-releasing hormone analogue (leuprolide) administered vaginally.
    Okada H; Sakura Y; Kawaji H; Yashiki T; Mima H
    Cancer Res; 1983 Apr; 43(4):1869-74. PubMed ID: 6403230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
    Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hormonal manipulation of disseminated prostatic cancer].
    Mahler C; Chaban M; Robinson M; Denis L
    Acta Urol Belg; 1984; 52(4):593-9. PubMed ID: 6097106
    [No Abstract]   [Full Text] [Related]  

  • 40. Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
    Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
    Int J Urol; 2006 Jan; 13(1):87-8. PubMed ID: 16448441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.